摘要:
Certain propanobicyclic amine compounds are described for treatment of CNS disorders such as psychotic disorders, convulsions, dystonia and cerebral ischemia. Compounds of particular interest are of the formula
wherein each of R 1 , R 2 , R 3 , R 4 , Y and Z is independently selected from hydrido, hydroxy, alkyl, cycloalkyl, cycloalkylalkyl, phenalkyl, phenyl, alkoxy, phenoxy, phenalkoxy, alkoxyalkyl, halo, haloalkyl and hydroxyalkyl; wherein R 3 and R 4 may be taken together to form oxo; wherein each of R 9 , R 10 , R", R 12 , R 13 and R 14 is independently selected from hydrido, alkyl, cycloalkyl, hydroxyalkyl, fluoroalkyl, cycloalkylalkyl, alkoxyalkyl, phenalkyl and phenyl; wherein G within the nitrogen-containing cyclohetero moiety is selected from
wherein R 15 is selected from hydrido, alkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenalkyl, alkoxyalkyl and hydroxyalkyl; wherein each of R 16 and R17 is independently selected from hydrido, hydroxy, alkyl, phenalkyl, phenyl, alkoxy, fluoroalkyl and fluoro; wherein m is one or two; wherein p is a number selected from zero through four, inclusive; wherein each of q and r is a number independently selected from one through three, inclusive, with the proviso that sum of q and r is a number from three through six, inclusive; with the further proviso that the nitrogen-containing cyclohetero moiety must be attached at one position selected from R 3 , R 4 , ring-position two, ring-position three and ring-position four; or the pharmaceutically-acceptable salts thereof.
摘要:
Substrates (such as cycloalkalnes, polycyclic hydrocarbons or aromatic compounds having methyl or methylene adjacent to their respective aromatic rings) are converted into oxides (such as ketones, alcohols or carboxylic acids) through oxygenation in the presence of an oxidation catalyst system comprising an imide compound of general formula (1) (such as N-hydroxyphthalimide) and a co-catalyst containing an element selected from the group consisting of group 2A elements of the periodic table, transition metals (group 3A to 7A, 8, 1B and 2B elements of the periodic table) and group 3B elements of the periodic table (except phosphovanadomolybdic acid) (wherein R?1 and R2¿ are each hydrogen or a substituent such as halogen, or alternatively R?1 and R2¿ may be united to form a double bond or an aromatic or non-aromatic 5- to 12-membered ring; X is O or OH; and n is 1 to 3).
摘要:
The present invention relates to 1,4-disubstituted piperazines of general formula (I), wherein X, Y, Z, R1, R2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.
摘要:
A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures of formula (I) (where the variables are as defined in the claims). The compounds are inhibitors of η-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.
摘要:
Methods of producing OLED materials containing fluorene ring systems in which two alkyl substituents at the 9-position of fluorene ring are alkyl substituted through key intermediates generically represented by the formula: where X represents a substituent that increases the acidity of the hydrogen atoms on the adjoining methylene group (which is immediately adjacent the fluorene ring systems 9 -position).
摘要:
Novel sulfamides of formula (I) are disclosed. The compounds exert an inhibitory action on the processing of APP by gamma-secretase, and are therefore useful in the treatment or prevention of Alzheimer's disease.
摘要:
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula (I), including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula (I).